# Primary Care Imaging using Optical Coherence Tomography

Stephen A. Boppart, M.D., Ph.D.

Bliss Professor of Engineering Beckman Institute for Advanced Science and Technology Electrical and Computer Engineering, Bioengineering, Medicine University of Illinois at Urbana-Champaign

April 12, 2012

IEEE Engineering in Medicine and Biology Society Syracuse Chapter Health Tech Symposium





#### **Disclosure:**

Royalties from patents licensed by MIT Consultant and research funding from Welch Allyn, Inc., Texas Instruments, Inc., and Samsung, Inc. Co-Founder and CMO of Diagnostic Photonics, Inc.





#### Emergency Room



#### Primary Care



## Healthcare System

Operating Room



#### **Motivation for this Research**



#### **Objective**

The development of an enhanced hand-held optical imaging instrument for use in the primary care office or general medical clinic.



#### **Motivation for this Research**



#### Result

Number of office visits increases dramatically in aging population, which is expected to continue to increase in the future.

► Majority of office visits are for diagnostic and screening services.

#### Advance Optical Biomedical Imaging Capabilities in the Front-Line Primary Care Instruments



# Ophthalmoscopy



## **Optical Coherence Tomography (OCT)**





#### 3-D Volume Acquisition

Dynamic Acquisition



- Cellular-level resolution
- Real-time volumetric imaging
- Digital computational analysis
- Intra-operative & intra-procedure feedback

## **Multi-Dimensional OCT Imaging**



## **Portable & Modular OCT Imaging System**



**Portable OCT** 





Surgical Microscope





- Compact & portable clinical system
- User-friendly software interface
- Modular beam delivery devices





**Optical Needle Probe** 

## **Optical Coherence Tomography** Rapid Development and Application



Zysk AM, Nguyen FT, Oldenburg AL, Marks DL, Boppart SA, J Biomed Optics, 12:051403, 2007

## **Optical Coherence Tomography** \$500M of Federally-Funded Research over last Decade



Swanson EA, OCT News, July 9, 2011

### **Optical Coherence Tomography**

#### **Rapid Commercial Development across Medical Specialties**















Swanson EA, OCT News, July 9, 2011

#### **Objective of this Research**



Transform OCT Technology from a Diagnostic Modality to a Screening Modality

- Advancing technology at the front-line
- Screening general population (normal/not?)
- Quantitative monitoring of chronic diseases
- Potentially more efficient and economic referral

#### Advanced Handheld Probe





*Compact OCT System* High speed, High resolution

#### **Important Tissue Sites in Primary Care Medicine**



Noninvasive Assessment of Biofilm Growth in the Middle Ear using a Portable Low-Coherence Interferometry System

> Finding and treating the source of chronic ear infections

## **Advance Point-of-Care Diagnostic and Imaging Technology in Primary Care Practice**

#### Otitis Media (OM) – Ear Infection Most frequent diagnosis for all children

60-80% have  $\geq 1$  OM by age 1 80-90% have  $\geq$  1 OM by age 3 17% have  $\geq$  3 OM by age 1 46% have  $\geq$  3 OM by age 3

#### Diagnoses

Acute OM OM with effusion (OME) - serous or secretory Chronic suppurative OM

#### Complications

Hearing loss, speech, language delays

#### Treatment

Antibiotics, surgery (tympanostomy), supportive care















## **National and Global Impact on Disability**



<u>Age-standardized disability-adjusted life year</u> (DALY) rates from otitis media by country (per 100,000 inhabitants)

Data from Mortality and Burden of Disease estimates for WHO member states in 2002

## **Biofilm Morphology and Growth**





<u>Biofilms account for ~ 80% of all infections</u> Urinary tract infections Indwelling catheters Dental plaque Contact lenses Prostheses <u>Complex polymicrobial communities</u> Protected from antibiotic exposure Rapidly develop antibiotic resistance Seed recurrent infections Developmental processes unknown Uncertain treatment protocols

## Three-Dimensional OCT of Developing Biofilms



3-day-old P.aerogenosa biofilm



#### Xi, et al., J Biomedical Optics, 11:034001, 2006



Comparison of Imaging Techniques



Fluorescence and confocal microscopy of the P.aerogenosa biofilm

3-day-old P.aerogenosa biofilm

Xi, et al., J Biomedical Optics, 11:034001, 2006

Direct Detection of Bacterial Biofilms on the Middle-Ear Mucosa of Children With Chronic Otitis Media

#### JAMA, 296:202-211, 2006

A Child 7, Right Ear, ROM; Culture NA, PCR NA





Above, illustration showing the location of the cochlear promontory in the middle ear where middle-ear mucosa (MEM) biopsy specimens where obtained. Left, MEM specimen showing only host-cell nuclei and no evidence of adherent bacterial clusters. Green fluorescence indicates live, healthy cells; red, dead cells; yellow and orange, cells with membrane damage.

#### B Child 5, Right Ear, OME; Culture NA, PCR+ (Streptococcus pneumoniae)





<u>26 Children undergoing tympanostomy tube placement</u>
13 (50%) had OME 20 (77%) had recurrent OM
7 (27%) had both diagnoses
27 of 52 (52%) of ears had effusions
Biofilms visualized by CLSM in 46 (92%) of 50 middle-ear biopsies

<u>3 children and 5 adults undergoing cochlear implantation (controls)</u> No biofilms observed in any of these mucosal biopsies

Will the diagnosis of a middle ear biofilm alter the antibiotic treatment protocol for chronic otitis media?

Can Low-Coherence Interferometry (LCI) or Optical Coherence Tomography (OCT) technology be used to determine the most appropriate therapy, most appropriate antibiotic, and follow response rates?

#### Use LCI or OCT to:

Diagnose, measure, and characterize biofilms. Characterize and quantify effusions. Measure precise TM changes under insufflation.



## **System Integration**















## **Otitis Media Induction Procedure in the Rat**

- Developed new animal biofilm model based on prior literature \*
- 30 µl of *Streptococcus pneumoniae* bacteria in saline with 1% methylcellulose solution (10<sup>10</sup> CFU/ml) inoculated into the nostrils of an anesthetized rat through a nasal cannula
- Immediately after inoculation, animal placed in a pressure chamber
- LCI otoscope used to examine the ears twice per week
- Entire procedure reproduced twice per week until the animal is unable to clear away fluid in the middle ear, and the presence of a biofilm is established
- Total 8 rats (6 infected, 2 control) over period of ~ 6 months







#### Video Image and Typical LCI Data of Normal Rat TM



- Translucent membrane in otoscope video
- Thin LCI peak trace representative of a thin normal TM

Nguyen, *et al.* Non-invasive optical interferometry for the assessment of biofilm growth in the middle ear. Biomedical Optics Express, 1:1104-1116, 2010

#### OCT and Histology of Normal Rat Tympanic Membrane

![](_page_24_Picture_1.jpeg)

**Scan Locations** 

![](_page_24_Figure_3.jpeg)

![](_page_24_Figure_4.jpeg)

Position 1

![](_page_24_Figure_6.jpeg)

Position 2

![](_page_24_Figure_8.jpeg)

![](_page_24_Picture_9.jpeg)

Histology

#### Position 3

#### Video Image and Typical LCI Data of Infected Rat TM

![](_page_25_Figure_1.jpeg)

- Red membrane and focal areas in otoscope video
- Scattering layers representative of biofilm behind thin TM

Nguyen, *et al.* Non-invasive optical interferometry for the assessment of biofilm growth in the middle ear. Biomedical Optics Express, 1:1104-1116, 2010

## **OCT and Histology of Infected Rat TM**

![](_page_26_Picture_1.jpeg)

Position 3

Position 4

Histology

## Automatic Classification Algorithm Hypothesis Testing

![](_page_27_Figure_1.jpeg)

• Use training data to set thresholds and classify scans

#### **Classification Models**

I. Normal Normal, 1. Normal, thin thin (animal)

Normal, 2. Normal thick 1 thick (edge, 3. Normal thick 2 human)

II. Biofilm Effusion 4. Thick effusion or effusion present 5. Clear effusion present

Biofilm6. New biofilmpresent7. Uniform biofilm

Biofilm + 8. Uniform biofilm effusion + clear effusion present 9. Uniform biofilm

+ thick effusion

10. New biofilm +clear effusion 11. New biofilm + thick effusion

Signal models 12-19 and 20-27 are repeated using 4-11 for normal and thick types (2, 3)

![](_page_28_Figure_9.jpeg)

![](_page_28_Figure_10.jpeg)

![](_page_28_Figure_11.jpeg)

![](_page_28_Figure_12.jpeg)

![](_page_28_Figure_13.jpeg)

![](_page_28_Figure_14.jpeg)

![](_page_28_Figure_15.jpeg)

![](_page_28_Figure_16.jpeg)

![](_page_28_Figure_17.jpeg)

#### **Classification of A-Scan Data**

![](_page_29_Figure_1.jpeg)

OCT Ophthalmoscopy for Screening and Monitoring of Diabetic Retinopathy

## Obesity, Diabetes, and Diabetic Retinopathy

 One-third (33.8%) of U.S. adults are obese
 Over one-third of children and adolescents are obese or overweight Reference: NHANES, CDC

![](_page_31_Figure_2.jpeg)

Diabetes

![](_page_31_Figure_4.jpeg)

1 in 10 (552 million) are expected to have diabetes by 2030
 40-45% of diabetics will have diabetic retinopathy

#### Proliferative Diabetic Retinopathy

![](_page_31_Picture_7.jpeg)

Retinal Neovascularization with Vitreous Hemorrhage

Disc Neovascularization with Vitreous Hemorrhage

![](_page_31_Picture_10.jpeg)

![](_page_31_Picture_11.jpeg)

Vision with diabetic retinopathy

**Reference: International Diabetes Foundation** 

## **Portable OCT System**

![](_page_32_Figure_1.jpeg)

Jung, et. al., IEEE TBME 58:741, 2011

## Four Quadrant 2 Axis Scanning MEMS Mirror

![](_page_33_Picture_1.jpeg)

![](_page_33_Picture_2.jpeg)

![](_page_33_Picture_3.jpeg)

#### Unique Gimble-free linkage configuration

![](_page_33_Picture_5.jpeg)

## Handheld Probe using MEMS Scanner

![](_page_34_Picture_1.jpeg)

#### **Anatomy of MEMS Probe**

![](_page_35_Figure_1.jpeg)

## Various Probe Designs

![](_page_36_Picture_1.jpeg)

![](_page_36_Picture_2.jpeg)

![](_page_36_Picture_3.jpeg)

![](_page_36_Picture_4.jpeg)

![](_page_36_Picture_5.jpeg)

#### In vivo OCT and Video Images (Human)

![](_page_37_Figure_1.jpeg)

![](_page_37_Picture_2.jpeg)

![](_page_37_Picture_3.jpeg)

(A) nail fold (B) uvula
(C) gum (D) arm (E) cornea
(F) tympanic membrane
(G) retina around fovea
(H) optic nerve head

Jung, et. al., IEEE TBME 58:741, 2011

## **Retinal OCT Images from Diabetic Patients**

![](_page_38_Figure_1.jpeg)

![](_page_38_Figure_2.jpeg)

## **Structure of Retinal Layers**

![](_page_39_Figure_1.jpeg)

NFL: Nerve fiber layer GCL: Ganglion cell layer IPL: Inner plexiforn layer INL: Inner nuclear layer OPL: Outer plexiforn layer ONL: Outer nuclear layerIS: Inner segmentOS: Outer segmentRPE: Retinal pigment epithelium

#### Diabetic retinopathy is a change in the thickness of retinal layers

#### **Segmentation of Retina Layers**

![](_page_40_Figure_1.jpeg)

Solid line: Manual segmentation; Dotted line: Automatic segmentation

#### Conclusions

- Vision for new technology and research in Primary Care Imaging using novel handheld scanners and portable OCT/LCI systems.
- Primary Care Imaging enables new technology at the frontline of healthcare for screening, quantitative monitoring, and potentially more effective referral practices.
- Experimental results show potential for advances in fundamental medical science of middle ear biofilms and retinal layer changes in diabetic retinopathy.
- Transform OCT to be a <u>Screening Modality</u>.

![](_page_41_Picture_5.jpeg)

## **Primary Care Imaging Research Partnership**

#### **NIH - NIBIB Bioengineering Research Partnership R01 EB013723**

![](_page_42_Picture_2.jpeg)

![](_page_42_Picture_3.jpeg)

![](_page_42_Picture_4.jpeg)

![](_page_43_Picture_0.jpeg)

## Acknowledgments

Beckman Institute for Advanced Science and Technology Biophotonics Imaging Laboratory Stephen Boppart, M.D., Ph.D.

Graduate Students Adeel Ahmad, M.S. Vasilica Crecea, M.S. Ben Graf, M.S. Joanne Li Yuan Liu, M.S. Guillermo Monroy Cac Nguyen, M.S. Nathan Shemonski, M.S. Fredrick South Jonathan Sun

Undergraduate Students Zita Hubler Jessica Hsu Eric Kuo Shreya Prakash Jonathan Rasio Wolfgang Rubrecht

Research Coordinator Darold Spillman

<u>Clinical Collaborators:</u> Otolaryngology: Ophthalmology: Primary Care - Pediatrics:

Kyungpook National University Jeehyun Kim, Ph.D., Mansik Jeon, Namhyun Cho, Sanyeop Han

Michael Novak, M.D. Samir I. Sayegh, M.D., Ph.D. Malcolm Hill, M.D.

> Advanced MEMS Daniel McCormick, Ph.D.

![](_page_43_Picture_10.jpeg)

Research Scientists Steven Adie, Ph.D. Eric Chaney Woonggyu Jung, Ph.D. Jongsick Kim, Ph.D. Marina Marjanovic, Ph.D. Haohua Tu, Ph.D. Youbo Zhao, Ph.D.

National Institutes of Health (NIBIB, NCI) National Science Foundation Carle Foundation Hospital Welch Allyn, Inc. & Blue Highway, LLC Texas Instruments, Inc. Samsung, Inc.

![](_page_43_Picture_13.jpeg)

## biophotonics.illinois.edu

![](_page_44_Picture_1.jpeg)

НОМЕ	
BACKGROUND	
RESEARCH	
PUBLICATIONS AND	
PRESENTATIONS	

PEOPLE

GALLERY

GROUP EVENTS

#### **BIOPHOTONICS IMAGING LABORATORY**

#### Welcome

![](_page_44_Picture_8.jpeg)

Located in the Beckman Institute for Advanced Science and Technology at the University of Illinois at Urbana-Champaign, the Biophotonics Imaging Laboratory, directed by Professor Stephen Boppart, is dedicated to the development of optical biomedical imaging techniques.

News

- In Biophotonics Imaging Lab Post-Doctoral Research Associate position available
- Biophotonics Imaging Lab to lead new NIH Bioengineering Research Partnership on Primary Care Imaging

![](_page_44_Picture_13.jpeg)

BECKMAN

![](_page_44_Picture_15.jpeg)

Carle Foundation

![](_page_44_Picture_17.jpeg)

UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN

Questions or Comments? Please contact us: jgsun2@illinois.edu. Website created by Jonathan Sun and Rick Valentine Copyright © 2005-2010, Stephen A. Boppart, Biophotonics Imaging Laboratory

![](_page_44_Picture_19.jpeg)

![](_page_45_Picture_0.jpeg)